{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:10:40Z","timestamp":1791497440525,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T00:00:00Z","timestamp":1624060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T00:00:00Z","timestamp":1624060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ministry of Health, Labor and Welfare Research Program on Rare and Intractable Diseases","award":["JPMH20FC1040"],"award-info":[{"award-number":["JPMH20FC1040"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10384-021-00847-3","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T04:03:00Z","timestamp":1624075380000},"page":"651-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Clinical features and symptoms of IgG4-related ophthalmic disease: a multicenter study"],"prefix":"10.1007","volume":"65","author":[{"given":"Hiroshi","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-ichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sogabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokuhide","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Azumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,19]]},"reference":[{"key":"847_CR1","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1056\/NEJM200103083441005","volume":"344","author":"H Hamano","year":"2001","unstructured":"Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732\u20138.","journal-title":"N Engl J Med"},{"key":"847_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","volume":"22","author":"H Umehara","year":"2012","unstructured":"Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21\u201330.","journal-title":"Mod Rheumatol"},{"key":"847_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire J-F, et al. The 2019 American college of rheumatology\/european league against rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79:77\u201387.","journal-title":"Ann Rheum Dis"},{"key":"847_CR4","first-page":"1","volume":"4","author":"H Umehara","year":"2020","unstructured":"Umehara H, Okazaki K, Kawa S, Takahashi H, Goto H, Matsui S, et al. The 2020 revised diagnostic criteria for IgG4-related disease. Mod Rheumatol. 2020;4:1\u201314.","journal-title":"Mod Rheumatol"},{"key":"847_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3109\/s10165-006-0518-Y","volume":"16","author":"M Yamamoto","year":"2006","unstructured":"Yamamoto M, Takahashi H, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, et al. A new conceptualization for Mikulicz\u2019s disease as an IgG4-related plasmacytic disease. Mod Rheumatol. 2006;16:335\u201340.","journal-title":"Mod Rheumatol"},{"key":"847_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00417-013-2548-4","volume":"252","author":"Y Sogabe","year":"2014","unstructured":"Sogabe Y, Ohshima K, Azumi A, Takahira M, Kase S, Tsuji H, et al. Location and frequency of lesions in patients with IgG4-related ophthalmic diseases. Graefes Arch Clin Exp Ophthalmol. 2014;252:531\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"847_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10384-014-0352-2","volume":"59","author":"H Goto","year":"2015","unstructured":"Goto H, Takahira M, Azumi A. Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol. 2015;59:1\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"847_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/358371","volume":"2012","author":"K Uchida","year":"2012","unstructured":"Uchida K, Masamune A, Shimosegawa T, Okazaki K. Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol. 2012;2012: 358371. https:\/\/doi.org\/10.1155\/2012\/358371.","journal-title":"Int J Rheumatol"},{"key":"847_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10384-013-0266-4","volume":"57","author":"Japanese Study Group of IgG4-Related Ophthalmic Disease","year":"2013","unstructured":"Japanese Study Group of IgG4-Related Ophthalmic Disease. A prevalence study of IgG4-related ophthalmic disease in Japan. Jpn J Ophthalmol. 2013;57:573\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"847_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","volume":"25","author":"V Deshpande","year":"2012","unstructured":"Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181\u201392.","journal-title":"Mod Pathol"},{"key":"847_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/WNO.0000000000000193","volume":"34","author":"S Kashii","year":"2014","unstructured":"Kashii S. IgG4-related disease: a neuro-ophthalmological perspective. J Neuroophthalmol. 2014;34:400\u20137.","journal-title":"J Neuroophthalmol"},{"key":"847_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12880-019-0347-z","volume":"19","author":"J Li","year":"2019","unstructured":"Li J, Zhang Y, Zhou H, Wang L, Wang Z, Li H. Magnetic resonance imaging indicator of the causes of optic neuropathy in IgG4-related ophthalmic disease. BMC Med Imaging. 2019;19:49.","journal-title":"BMC Med Imaging"},{"key":"847_CR13","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/bjophthalmol-2017-311519","volume":"102","author":"JW Hong","year":"2018","unstructured":"Hong JW, Kang S, Song MK, Ahn CJ, Sa HS. Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2018;102:1591\u20135.","journal-title":"Br J Ophthalmol"},{"key":"847_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000006205","volume":"96","author":"M Ebbo","year":"2017","unstructured":"Ebbo M, Patient M, Grados A, Groh M, Desblaches J, Hachulla E, et al. Ophthalmic manifestations in IgG4-related disease: clinical presentation and response to treatment in a French case-series. Medicine. 2017;96: e6205. https:\/\/doi.org\/10.1097\/md.0000000000006205.","journal-title":"Medicine"},{"key":"847_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","volume":"78","author":"ZS Wallace","year":"2019","unstructured":"Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78:406\u201312.","journal-title":"Ann Rheum Dis"},{"key":"847_CR16","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.7754\/Clin.Lab.2017.170403","volume":"63","author":"S Kawa","year":"2017","unstructured":"Kawa S, Skold M, Ramsden DB, Parker A, Harding SJ. Serum IgG4 concentration in IgG4-related disease. Clin Lab. 2017;63:1323\u201337.","journal-title":"Clin Lab"},{"key":"847_CR17","first-page":"256","volume":"101","author":"YJ Woo","year":"2017","unstructured":"Woo YJ, Kim JW, Yoon JS. Clinical implications of serum IgG4 levels in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2017;101:256\u201360.","journal-title":"Br J Ophthalmol"},{"key":"847_CR18","doi-asserted-by":"publisher","first-page":"e4002-e","DOI":"10.1097\/MD.0000000000004002","volume":"95","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Kostov B, Bosch X, Acar-Denizli N, Ramos-Casals M, Stone JH. Therapeutic approach to IgG4-related disease: a systematic review. Medicine. 2016;95:e4002-e. https:\/\/doi.org\/10.1097\/MD.0000000000004002.","journal-title":"Medicine"},{"key":"847_CR19","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1136\/gut.2006.115246","volume":"56","author":"K Hirano","year":"2007","unstructured":"Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56:1719\u201324.","journal-title":"Gut"},{"key":"847_CR20","doi-asserted-by":"publisher","first-page":"10262","DOI":"10.1038\/s41598-018-28405-x","volume":"8","author":"M Shirakashi","year":"2018","unstructured":"Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep. 2018;8:10262. https:\/\/doi.org\/10.1038\/s41598-018-28405-x.","journal-title":"Sci Rep"},{"key":"847_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/bjophthalmol-2015-307164","volume":"100","author":"NH Andrew","year":"2016","unstructured":"Andrew NH, Gajdatsy A, Selva D. Intraorbital corticosteroid injection for the treatment of IgG4-related ophthalmic disease. Br J Ophthalmol. 2016;100:644\u20137.","journal-title":"Br J Ophthalmol"},{"key":"847_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000295","volume":"4","author":"J Ominato","year":"2019","unstructured":"Ominato J, Oyama T, Cho H, Shiozaki N, Umezu H, Takizawa J, et al. The natural course of IgG4-related ophthalmic disease after debulking surgery: a single-centre retrospective study. BMJ Open Ophthalmol. 2019;4: e000295. https:\/\/doi.org\/10.1136\/bmjophth-2019-000295.","journal-title":"BMJ Open Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00847-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-021-00847-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00847-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:07:39Z","timestamp":1629677259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-021-00847-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,19]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["847"],"URL":"https:\/\/doi.org\/10.1007\/s10384-021-00847-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,19]]},"assertion":[{"value":"5 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H. Goto, None; S. Ueda, None; R. Nemoto, None; K. Ohshima, None; Y. Sogabe, None; K. Kitagawa, None; Y. Ogawa, None; T. Oyama, None; M. Furuta, None; A. Azumi, None; M. Takahira, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}